Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Dishman Carbogen Amcis Ltd. ( (IN:DCAL) ) is now available.
Dishman Carbogen Amcis Ltd. announced the approval of its un-audited financial results for the second quarter and half-year ending September 30, 2025, during a board meeting held on November 4, 2025. The results, prepared in accordance with SEBI regulations, were accompanied by a limited review report from the company’s statutory auditors, indicating a transparent disclosure of financial performance. Additionally, a certificate on security cover for non-convertible debentures was also provided, reflecting the company’s commitment to regulatory compliance and financial transparency.
More about Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Ltd. operates in the pharmaceutical industry, focusing on the production and development of active pharmaceutical ingredients and intermediates. The company caters to global pharmaceutical markets, providing services and products that support drug development and manufacturing processes.
Average Trading Volume: 21,451
Technical Sentiment Signal: Buy
Current Market Cap: 45.73B INR
See more data about DCAL stock on TipRanks’ Stock Analysis page.